KRAS and colorectal carcinoma: From the CRCs and PDACs for which we could detect a mutation in the KRAS gene, we were able to confirm its presence in 80% of the CRC-derived (4/5) and 90% of the PDAC-derived (10/11) tumor organoids (Figure 2C).